Table 1.
Characteristics of HCV patients and healthy controls.
| HCV stage | N | Age | Sex (M:F) | ALT | Viral load IU/ml | GT | Days PI | Risk | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| A | 25 | F | 148 | 16726 | 1b | 65 | surgery | R | |
| A | 58 | M | 53 | UD | ND | 80 | surgery | R | |
| A | 44 | M | 22 | UD | 3 (sero) | 230 | sex | R | |
| A | 40 | F | 14 | UD | 1 (sero) | 115 | sex | R | |
| A | 13 | M | 125 | 5067 | 1a | 70 | ND | R | |
| A | 26 | M | 144 | 7553 | 1 (sero) | 90 | IDU | R | |
| A | 38 | M | 30 | < 615 | ND | 60 | intranasal | R | |
| A | 29 | F | 175 | UD | 1 | 120 | ND | R | |
| A | 31 | M | 1621 | 500000 | 1a | ND | IDU | R | |
| A | 30 | M | 336 | 363000 | 1a | 200 | IDU | C | |
| A | 34 | F | 39 | 2745 | 1 | 55 | sex | C | |
| A | 54 | M | 1446 | > 700000 | 1 | 30 | stick | C | |
| A | 20 | M | 39 | 280 | 1a | 130 | IDU | C | |
| A | 20 | M | 32 | 11500 | 1b | 150 | IDU | C | |
| A | 26 | M | 441 | 335000 | 1b | 100 | ND | C | |
| A | 62 | F | 91 | 850001 | 1a | 60 | Transfusion | C | |
| A | 54 | F | 733 | 5050 | 2 | 90 | stick | C | |
| A | 38 | M | 253 | 130111 | 4 | ND | IDU | C | |
| A | 26 | M | 957 | 627000 | 4a | ND | Shared razor | C | |
| A | 28 | F | 82 | 2680000 | 3 | 60 | ND | C | |
| Acute Median (range) | 20 |
31 (13–62) |
13:7 |
135 (14–1621) |
9527 (0–2680000) |
90 (30–230) |
|||
| Resolved Median (range) | 12 |
46 (37–55) |
4:5 |
22 (8–94) |
0 |
||||
| Chronic Median (range) | 11 |
38 (24–76) |
7:4 |
44 (15–79) |
500000 (0–2900000) |
||||
| Negative Median (range) | 14 |
26 (22–57) |
4:10 |
ND |
0 |
A, acute; R, resolved; C, chronic; N, number of patients; M, male; F, female; ALT, alanine aminotransferase; IU, international units; UD, undetectable; GT, genotype; PI, postinfection; ND, not determined; IDU, injection drug user.